open access
COVID-19 and diabetes: a deadly duo?
, 2, 3
Affiliations- Faculty of Medicine, Nicolaus Copernicus University in Torun, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Poland
- Department of Cardiology and Internal Medicine, Nicolaus Copernicus University in Torun, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Poland
- Antoni Jurasz University Hospital No. 1., Nicolaus Copernicus University in Torun, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Poland
open access
Abstract
Introduction: Among the patients with severe or fatal COVID-19 a high prevalence of comorbidities is
noted, diabetes being one of them. The objective of the study was to analyse the relation of COVID-19
and diabetes in respect of their influence on hospitalization’s length and outcome.
Materials and methods: The data acquired from the database of Antoni Jurasz University Hospital No.
1 in Bydgoszcz were analysed. The analysis included 1,051 adult COVID-19 positive patients that were
hospitalized between March 14, 2020, and April 12, 2021. The collected data included a history of diabetes
with differentiation between type 1 and type 2, hospitalization outcome (discharge or death), length
of hospital stay.
Results: The prevalence of diabetes in the study group was determined to be 2.09% and 10.18% for
diabetes type 1 and 2, respectively, totalling 12.27% (n = 129). Most of the patients (87.54%) have been
discharged while 12.46% have died. The diabetic patients accounted for 11.63% of the discharges and
16.79% of deaths. The mortality rates in the group of insulin-dependent diabetes were the highest, namely
27.27% vs. 12.15% in the reaming study population (p = 0.0720). Hospitalization’s length did not differ
according to diabetes occurrence as on average it amounted to 15.90 days in diabetic patients and 14.44
days in non-diabetic ones.
Conclusions: COVID-19 and type 1 diabetes may constitute a deadly duo. Further studies that include
patients with insulin-dependent diabetes are needed to better understand the impact of diabetes and
COVID-19 on mortality and hospitalization’s length.
Abstract
Introduction: Among the patients with severe or fatal COVID-19 a high prevalence of comorbidities is
noted, diabetes being one of them. The objective of the study was to analyse the relation of COVID-19
and diabetes in respect of their influence on hospitalization’s length and outcome.
Materials and methods: The data acquired from the database of Antoni Jurasz University Hospital No.
1 in Bydgoszcz were analysed. The analysis included 1,051 adult COVID-19 positive patients that were
hospitalized between March 14, 2020, and April 12, 2021. The collected data included a history of diabetes
with differentiation between type 1 and type 2, hospitalization outcome (discharge or death), length
of hospital stay.
Results: The prevalence of diabetes in the study group was determined to be 2.09% and 10.18% for
diabetes type 1 and 2, respectively, totalling 12.27% (n = 129). Most of the patients (87.54%) have been
discharged while 12.46% have died. The diabetic patients accounted for 11.63% of the discharges and
16.79% of deaths. The mortality rates in the group of insulin-dependent diabetes were the highest, namely
27.27% vs. 12.15% in the reaming study population (p = 0.0720). Hospitalization’s length did not differ
according to diabetes occurrence as on average it amounted to 15.90 days in diabetic patients and 14.44
days in non-diabetic ones.
Conclusions: COVID-19 and type 1 diabetes may constitute a deadly duo. Further studies that include
patients with insulin-dependent diabetes are needed to better understand the impact of diabetes and
COVID-19 on mortality and hospitalization’s length.
Keywords
SARS-CoV-2, coronavirus, mortality, length of stay, insulin-dependent, type 1 diabetes, type 2 diabetes
About this articleTitle
COVID-19 and diabetes: a deadly duo?
Journal
Issue
Article type
Original article
Pages
119-124
Published online
2021-06-30
Page views
413
Article views/downloads
541
DOI
Bibliographic record
Medical Research Journal 2021;6(2):119-124.
Keywords
SARS-CoV-2
coronavirus
mortality
length of stay
insulin-dependent
type 1 diabetes
type 2 diabetes
Authors
Klaudyna Grzelakowska
Michał Kasprzak
Jacek Kryś
References (17)- Apicella M, Campopiano MC, Mantuano M, et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020; 8(9): 782–792.
- Saeedi P, Salpea P, Karuranga S, et al. IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9 edition. Diabetes Res Clin Pract. 2019; 157: 107843.
- Seiglie J, Platt J, Cromer SJ, et al. Diabetes as a risk factor for poor early outcomes in patients hospitalized with COVID-19. Diabetes Care. 2020; 43(12): 2938–2944.
- Knapp S. Diabetes and infection: is there a link?--A mini-review. Gerontology. 2013; 59(2): 99–104.
- Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Diabetes Res Clin Pract. 2020; 162: 108142.
- Ma RCW, Holt RIG. COVID-19 and diabetes. Diabet Med. 2020; 37(5): 723–725.
- Akbariqomi M, Hosseini MS, Rashidiani J, et al. Clinical characteristics and outcome of hospitalized COVID-19 patients with diabetes: A single-center, retrospective study in Iran. Diabetes Res Clin Pract. 2020; 169: 108467.
- Vargas-Vázquez A, Bello-Chavolla OY, Ortiz-Brizuela E, et al. Impact of undiagnosed type 2 diabetes and pre-diabetes on severity and mortality for SARS-CoV-2 infection. BMJ Open Diabetes Res Care. 2021; 9(1).
- Wang F, Cao J, Yu Y, et al. Epidemiological characteristics of patients with severe COVID-19 infection in Wuhan, China: evidence from a retrospective observational study. Int J Epidemiol. 2021; 49(6): 1940–1950.
- You JiH, Lee SAh, Chun SY, et al. Clinical outcomes of COVID-19 patients with type 2 diabetes: A population-based study in Korea. Endocrinol Metab (Seoul). 2020; 35(4): 901–908.
- Sonmez A, Demirci I, Haymana C, et al. Clinical characteristics and outcomes of COVID-19 in patients with type 2 diabetes in Turkey: A nationwide study (TurCoviDia). J Diabetes. 2021; 13(7): 585–595.
- Ruan Y, Ryder REJ, De P, et al. ABCD Covid-19 audit group. A UK nationwide study of people with type 1 diabetes admitted to hospital with COVID-19 infection. Diabetologia. 2021 [Epub ahead of print].
- McGurnaghan SJ, Weir A, Bishop J, et al. Public Health Scotland COVID-19 Health Protection Study Group, Scottish Diabetes Research Network Epidemiology Group. Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes Endocrinol. 2021; 9(2): 82–93.
- Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020; 8(10): 813–822.
- Cariou B, Hadjadj S, Wargny M, et al. CORONADO investigators. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020; 63(8): 1500–1515.
- Al-Salameh A, Lanoix JP, Bennis Y, et al. Characteristics and outcomes of COVID-19 in hospitalized patients with and without diabetes. Diabetes Metab Res Rev. 2021; 37(3): e3388.
- Alkundi A, Mahmoud I, Musa A, et al. Clinical characteristics and outcomes of COVID-19 hospitalized patients with diabetes in the United Kingdom: A retrospective single centre study. Diabetes Res Clin Pract. 2020; 165: 108263.